128 related articles for article (PubMed ID: 16467135)
1. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.
Ma JD; Nafziger AN; Rhodes G; Liu S; Bertino JS
Drug Metab Dispos; 2006 May; 34(5):783-5. PubMed ID: 16467135
[TBL] [Abstract][Full Text] [Related]
2. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.
Ma JD; Nafziger AN; Rhodes G; Liu S; Gartung AM; Bertino JS
J Clin Pharmacol; 2006 Jan; 46(1):103-8. PubMed ID: 16397289
[TBL] [Abstract][Full Text] [Related]
3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
4. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
6. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
7. The interaction between St John's wort and an oral contraceptive.
Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
[TBL] [Abstract][Full Text] [Related]
8. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
9. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
[TBL] [Abstract][Full Text] [Related]
10. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
11. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Chung E; Nafziger AN; Kazierad DJ; Bertino JS
Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
[TBL] [Abstract][Full Text] [Related]
12. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.
Okudaira T; Kotegawa T; Imai H; Tsutsumi K; Nakano S; Ohashi K
J Clin Pharmacol; 2007 Jul; 47(7):871-6. PubMed ID: 17585116
[TBL] [Abstract][Full Text] [Related]
13. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
15. The effect of hormone replacement therapy on CYP3A activity.
Gorski JC; Wang Z; Haehner-Daniels BD; Wrighton SA; Hall SD
Clin Pharmacol Ther; 2000 Oct; 68(4):412-7. PubMed ID: 11061581
[TBL] [Abstract][Full Text] [Related]
16. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.
Rogers JF; Morrison AL; Nafziger AN; Jones CL; Rocci ML; Bertino JS
Clin Pharmacol Ther; 2002 Dec; 72(6):711-7. PubMed ID: 12496752
[TBL] [Abstract][Full Text] [Related]
17. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
18. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.
Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD
Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]